WO2005047260A1 - Process for preparing gatifloxacin - Google Patents

Process for preparing gatifloxacin Download PDF

Info

Publication number
WO2005047260A1
WO2005047260A1 PCT/IB2004/003595 IB2004003595W WO2005047260A1 WO 2005047260 A1 WO2005047260 A1 WO 2005047260A1 IB 2004003595 W IB2004003595 W IB 2004003595W WO 2005047260 A1 WO2005047260 A1 WO 2005047260A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
gatifloxacin
process according
boron trifluoride
isolated
Prior art date
Application number
PCT/IB2004/003595
Other languages
French (fr)
Inventor
Antonio Cosme Gomez
Javier Villasante Prieto
Francisco Palomo Nicolau
Original Assignee
Quimica Sintetica, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quimica Sintetica, S.A. filed Critical Quimica Sintetica, S.A.
Publication of WO2005047260A1 publication Critical patent/WO2005047260A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention relates to a simplified process for preparing gatifloxacin, which avoids isolation of the intermediate compounds (denominated "one pot” process) .
  • Gatifloxacin is the international common name of l-cyclopropyl-6-fluoro-l, 4-dihydro-8-methoxy- 1- (3-methyl-l-piperazinyl) -4-oxo-3-guinolin-carboxylic acid of formula (I) , with application in medicine and known for its antibiotic activity:
  • EP-A-230295 discloses a process for obtaining gatifloxacin that consists on the reaction of compound (II) with 2-
  • Gatifloxacin (I) (IV) This process uses the intermediate compound (III) , which has been prepared and isolated in a separate operation, while the intermediate compound (IV) is also isolated before proceeding to its conversion into gatifloxacin by treatment with ethanol in the presence of triethylamine. The overall yield from these three steps is lower than 40%.
  • These disadvantages a synthesis involving several steps, low yields, and the need to isolate the intermediate products — hinder the production of gatifloxacin on an industrial scale. There is therefore a need to provide a process for preparing gatifloxacin with a good chemical yield, without the need to isolate the intermediate compounds and that substantially avoids demethylation in position 8 of the ring.
  • the object of this invention is a simplified process for preparing gatifloxacin which does not require isolation of the intermediate compounds .
  • a silylating agent of formula ZSiR 3 in which Z is Me 3 SiNH- or C1-, and R is either a C1-C4 alkyl chain or phenyl, within an aprotic polar solvent, for obtaining the intermediate compound (V) , in which R is either a C ⁇ -C 4 alkyl chain or phenyl, which without being isolated is then reacted with a boron trifluoride compound to prepare the intermediate compound (III) ,
  • the silylating agents of formula ZSiR 3 in which Z is MeaSi H- o C1-, and R is either a C1.-C4 alkyl chain or phenyl, are compounds which can convert the hydroxyl group of a carboxylic acid into a trialkyl, triarylsilyl or triarylalkylsilyl group in order to protect it or to activate it in subsequent reactions.
  • the silylating agents can be chosen from the group of compounds such as: hexamethyldisilazane (HMDS) , and those described in the book “Protective Groups in Organic Synthesis” by T.W.Greene and P.G.M.Wuts, Third Edition, Editorial John Wiley & Sons, 1999 (ISBN 0-471-16019-9) (Pages 428-431) such as trimethylsilyl chloride, tert-butyldimethylsilyl chloride, isopropyldimethylsilyl chloride, di-tert- butyimethylsilyl chloride, phenyldimethylsilyl chloride, triisopropylsilyl chloride.
  • HMDS hexamethyldisilazane
  • the silylating agent used is hexamethyldisilazane (HMDS) .
  • HMDS hexamethyldisilazane
  • the aprotic polar solvents are known for a skilled man in the art and are those organic solvents which have a certain polarity but which do not have acid hydrogen atoms .
  • the book "Advanced Organic Chemistry” by J. March, 3rd Edition, published by John Wiley & Sons, 1985 (Table 13, page 319) contains a list of solvents arranged by decreasing polarity, among which can be distinguished the following aprotic polar solvents: acetonitryl, dimethylsulphoxide di ethylformamide.
  • the aprotic polar solvent used is acetonitryl.
  • the boron trifluoride compound is a compound able to form chelates between oxygen atoms, and can be selected from the group of compounds such as: boron trifluoride, complex of boron trifluoride and diethyl ether (boron trifluoride ehtyletherate: BF 3 .Et 2 0) , complex of boron trifluoride and tetrahydrofuran, tetrafluoroboric acid, complex of tetrafluoroboric acid and dimethyl ether.
  • the boron trifluoride compound used is the complex of boron trifluoride ethyletherate.
  • the C 1 -C 4 alkyl alcohol can be selected from the group of compounds such as: methanol, ethanol, isopropanol, 1-propanol, 1-butanol, isobutanol, sec- butanol and tert-butanol.
  • the C1-C4 alcohol is methanol.
  • the compound (II) reacts with the silylating agent at a temperature ranging between 70 and 85° C within the aprotic polar solvent for a period of time ranging between 1 and 2 hours.
  • the intermediate compound (V) reacts with the boron trifluoride compound within the aprotic polar solvent at a temperature ranging between 15 and 25 °C until the compound (V) is observed to have disappeared completely.
  • the bases are compounds which give water an alkaline pH and can be both inorganic and organic.
  • the inorganic bases include the alkaline or alkaline-earth bicarbonates and carbonates.
  • the organic bases include the tertiary amines.
  • the tertiary amines include, for example: triethylamine, tributylamine, 4- methylmorpholine and 4-dimethylaminopryrridine. Preferably, triethylamine is used.
  • the intermediate compound (III) reacts with
  • the precipitate obtained is gatifloxacin (I) , which is filtered, washed with the cold C1-C4 alcohol and dried at 40° C until a constant weight is obtained. Eventually, the crude gatifloxacin obtained can be recrystallised in methanol. Surprisingly, it has been found that the new process allows gatifloxacin to be obtained with a yield exceeding 75% on the basis of the compound (II) , without being needed to isolate the intermediates involved in the various synthetic steps, with a purity and a quality suitable for preparing pharmaceutical formulations, and with a content of less than 0.1% of the by-product resulting from demethylation in position 8 of the ring.
  • the example which follows below is set out solely for the purposes of providing a detailed explanation of the process object of the invention for the skilled men in the art.
  • the reaction mixture is cooled to a temperature ranging between 0 and 15° C, and 5.78 g (0.0407 moles, 1.2 equivalents) of boron trifluoride ethyletherate is added while keeping the temperature below 15° C. Once addition is completed, the temperature is allowed to rise to 15- 25° C and it is kept under these conditions for approximately 2 hours.
  • the pH of the mixture is then adjusted to an approximate value of 9 with triethylamine (approximately 2 ml) .
  • To the resulting suspension is added a solution of 10.19 g (0.1017 moles, 3 equivalents) of 2-methylpiperazine in 28 ml of acetonitryl, while maintaining the temperature between 15 and 25° C.
  • the resulting amber solution is kept with stirring under these conditions for approximately 3 hours .
  • the solution is distilled at low pressure until a stirrable paste is obtained.
  • 50 ml of methanol is added, the resulting suspension is raised to a temperature of 63-67° C and is kept under these conditions for approximately 5 hours .
  • the mixture is cooled to a temperature of 25-35° C in a water bath, and then at a temperature of 0-5° C in a water/ice bath for a further 1 hour.
  • the resulting precipitate is filtered, washed with cold methanol (2 x 10 ml) and dried at 40° C in a vacuum oven to constant weight. 10.70 g of crude gatifloxacin is obtained, having a water content of 2.95% by weight.
  • the yield of the process is 81.8%.
  • the crude product is crystallised in methanol by dissolving 20 g of crude gatifloxacin in 1 1 of methanol (50 volumes) at a temperature of 63-67° C. Once all the product has been dissolved, the solution is left to cool to a temperature of 30-40° C, and then to a temperature of 0-5° C in a water/ice bath, maintaining it under these conditions for 1 hour. The resulting suspension is filtered and the solid retained is washed with 20 ml (1 volume) of cold methanol. The solid obtained is dried at 40° C in a vacuum oven to provide 18.65 g of gatifloxacin with a water content of 2.36% by weight.
  • the overall yield from the compound (II) is 77.7%, with a purity exceeding 99.8% as determined by HPLC chromatography.
  • the content of by-product resulting from demethylation in position 8 of the ring is lower than 0.1% as determined by HPLC chromatography.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a simplified process for preparing gatifloxacin. In said process the compound (II) is used as the starting compund, which is then made to react with 2-methylpiperazine after being silyated and activated in the form of boron chelate.Finally, the boron chelate is eliminated by treatment with a C1-C4 alkyl chain alcohol. One characteristic of the process described is that all the reactions are carried out without isolating the intermediate compounds formed ('one pot' process).

Description

PROCESS FOR PREPARING GATIFLOXACIN
Field of the technique This invention relates to a simplified process for preparing gatifloxacin, which avoids isolation of the intermediate compounds (denominated "one pot" process) .
Prior state of the art Gatifloxacin is the international common name of l-cyclopropyl-6-fluoro-l, 4-dihydro-8-methoxy- 1- (3-methyl-l-piperazinyl) -4-oxo-3-guinolin-carboxylic acid of formula (I) , with application in medicine and known for its antibiotic activity:
Figure imgf000002_0001
European patent application EP-A-230295 discloses a process for obtaining gatifloxacin that consists on the reaction of compound (II) with 2-
Figure imgf000002_0002
In this process the gatifloxacin is isolated in the form of a hemihydrate after a laborious process of column chromatography and recrystallisation in methanol, which contributes towards making the final yield lower than 20% by weight. Moreover, in said process an undesired by-product is formed, resulting from demethylation at position 8 of the ring. European patent application EP-A-241206 discloses a process for preparing gatifloxacin, whose final steps are as follows:
Figure imgf000003_0001
(III) H ft N Me H DMSO
Gatifloxacin (I)
Figure imgf000003_0002
(IV) This process uses the intermediate compound (III) , which has been prepared and isolated in a separate operation, while the intermediate compound (IV) is also isolated before proceeding to its conversion into gatifloxacin by treatment with ethanol in the presence of triethylamine. The overall yield from these three steps is lower than 40%. These disadvantages — a synthesis involving several steps, low yields, and the need to isolate the intermediate products — hinder the production of gatifloxacin on an industrial scale. There is therefore a need to provide a process for preparing gatifloxacin with a good chemical yield, without the need to isolate the intermediate compounds and that substantially avoids demethylation in position 8 of the ring. The processes termed in English "one pot" are characterised in that the synthesis is carried out in the same reaction vessel, without isolating the intermediate compounds, and by means of successive addition of the reacting compounds. The authors of the present invention have discovered a simplified process for preparing gatifloxacin which does not require isolation of the intermediate compounds .
Object of the invention The object of this invention is a simplified process for preparing gatifloxacin which does not require isolation of the intermediate compounds .
Detailed description of the invention The process object of the invention consists on reacting the compound (II)
Figure imgf000004_0001
with a silylating agent of formula ZSiR3, in which Z is Me3SiNH- or C1-, and R is either a C1-C4 alkyl chain or phenyl, within an aprotic polar solvent, for obtaining the intermediate compound (V) ,
Figure imgf000005_0001
in which R is either a Cχ-C4 alkyl chain or phenyl, which without being isolated is then reacted with a boron trifluoride compound to prepare the intermediate compound (III) ,
Figure imgf000005_0002
which is not isolated and is then reacted with 2- ethylpiperazin after adjusting the pH to a value in the range of 8.5 to 9.5, to obtain the intermediate compound (IV) ,
Figure imgf000005_0003
which without being isolated is reacted with a C1-C chain alcohol in order to prepare gatifloxacin (I) . The compound (II) can be prepared according to the process described in preparation no. 6 of European patent application EP-A-241206. The silylating agents of formula ZSiR3, in which Z is MeaSi H- o C1-, and R is either a C1.-C4 alkyl chain or phenyl, are compounds which can convert the hydroxyl group of a carboxylic acid into a trialkyl, triarylsilyl or triarylalkylsilyl group in order to protect it or to activate it in subsequent reactions. The silylating agents can be chosen from the group of compounds such as: hexamethyldisilazane (HMDS) , and those described in the book "Protective Groups in Organic Synthesis" by T.W.Greene and P.G.M.Wuts, Third Edition, Editorial John Wiley & Sons, 1999 (ISBN 0-471-16019-9) (Pages 428-431) such as trimethylsilyl chloride, tert-butyldimethylsilyl chloride, isopropyldimethylsilyl chloride, di-tert- butyimethylsilyl chloride, phenyldimethylsilyl chloride, triisopropylsilyl chloride. Preferably, the silylating agent used is hexamethyldisilazane (HMDS) . The aprotic polar solvents are known for a skilled man in the art and are those organic solvents which have a certain polarity but which do not have acid hydrogen atoms . The book "Advanced Organic Chemistry" by J. March, 3rd Edition, published by John Wiley & Sons, 1985 (Table 13, page 319) , contains a list of solvents arranged by decreasing polarity, among which can be distinguished the following aprotic polar solvents: acetonitryl, dimethylsulphoxide di ethylformamide. Preferably, the aprotic polar solvent used is acetonitryl.
The boron trifluoride compound is a compound able to form chelates between oxygen atoms, and can be selected from the group of compounds such as: boron trifluoride, complex of boron trifluoride and diethyl ether (boron trifluoride ehtyletherate: BF3.Et20) , complex of boron trifluoride and tetrahydrofuran, tetrafluoroboric acid, complex of tetrafluoroboric acid and dimethyl ether. Preferably, the boron trifluoride compound used is the complex of boron trifluoride ethyletherate. The C1-C4 alkyl alcohol can be selected from the group of compounds such as: methanol, ethanol, isopropanol, 1-propanol, 1-butanol, isobutanol, sec- butanol and tert-butanol. Preferably, the C1-C4 alcohol is methanol. The compound (II) reacts with the silylating agent at a temperature ranging between 70 and 85° C within the aprotic polar solvent for a period of time ranging between 1 and 2 hours. The intermediate compound (V) reacts with the boron trifluoride compound within the aprotic polar solvent at a temperature ranging between 15 and 25 °C until the compound (V) is observed to have disappeared completely. At this point the pH of the mixture is adjusted with a base to a value between 8.5 and 9.5. The bases are compounds which give water an alkaline pH and can be both inorganic and organic. The inorganic bases include the alkaline or alkaline-earth bicarbonates and carbonates. The organic bases include the tertiary amines. The tertiary amines include, for example: triethylamine, tributylamine, 4- methylmorpholine and 4-dimethylaminopryrridine. Preferably, triethylamine is used. The intermediate compound (III) reacts with
2-methylpiperazine within the aprotic polar solvent at a pH between 8.5 and 9.5, keeping the temperature within a range of 15 to 25° C for approximately 3 hours, until complete conversion of the compound (III) is observed. Distillation at low pressure is then carried out until a stirrable paste is obtained. The C1-C4 alkyl alcohol is added to that paste in order to remove the boron chelate, at a temperature ranging between 60 and 70° C, for the time necessary to achieve the completion of the reaction of compound ( IV) , approximately 5 hours . Once the boron chelate elimination reaction has been completed the mixture is cooled, first to a temperature ranging between 25 and 35° C, and then to between 0 and 5° C. The precipitate obtained is gatifloxacin (I) , which is filtered, washed with the cold C1-C4 alcohol and dried at 40° C until a constant weight is obtained. Eventually, the crude gatifloxacin obtained can be recrystallised in methanol. Surprisingly, it has been found that the new process allows gatifloxacin to be obtained with a yield exceeding 75% on the basis of the compound (II) , without being needed to isolate the intermediates involved in the various synthetic steps, with a purity and a quality suitable for preparing pharmaceutical formulations, and with a content of less than 0.1% of the by-product resulting from demethylation in position 8 of the ring. The example which follows below is set out solely for the purposes of providing a detailed explanation of the process object of the invention for the skilled men in the art.
Example 1: Preparing gatifloxacin from compound (II) 10 g (0.0339 moles, 1 equivalent) of compound
(II) is placed in a flask, 30 ml of acetonitryl (3 volumes) is added and this is heated to a temperature of 76-80° C. Once reflux has been attained, and being the temperature maintained, 3.28 g (0.0203 moles, 0.6 equivalents) of hexamethyldisilazane (HMDS) is added with a compensated adding funnel. Once addition is completed, the reaction is maintained with stirring for 1 hour at a temperature of 76-80° C. Once this period has elapsed, the reaction mixture is cooled to a temperature ranging between 0 and 15° C, and 5.78 g (0.0407 moles, 1.2 equivalents) of boron trifluoride ethyletherate is added while keeping the temperature below 15° C. Once addition is completed, the temperature is allowed to rise to 15- 25° C and it is kept under these conditions for approximately 2 hours. The pH of the mixture is then adjusted to an approximate value of 9 with triethylamine (approximately 2 ml) . To the resulting suspension is added a solution of 10.19 g (0.1017 moles, 3 equivalents) of 2-methylpiperazine in 28 ml of acetonitryl, while maintaining the temperature between 15 and 25° C. The resulting amber solution is kept with stirring under these conditions for approximately 3 hours . Once the reaction has been completed, the solution is distilled at low pressure until a stirrable paste is obtained. At this point 50 ml of methanol is added, the resulting suspension is raised to a temperature of 63-67° C and is kept under these conditions for approximately 5 hours . Once the reaction has been completed, the mixture is cooled to a temperature of 25-35° C in a water bath, and then at a temperature of 0-5° C in a water/ice bath for a further 1 hour. The resulting precipitate is filtered, washed with cold methanol (2 x 10 ml) and dried at 40° C in a vacuum oven to constant weight. 10.70 g of crude gatifloxacin is obtained, having a water content of 2.95% by weight. The yield of the process is 81.8%.
The crude product is crystallised in methanol by dissolving 20 g of crude gatifloxacin in 1 1 of methanol (50 volumes) at a temperature of 63-67° C. Once all the product has been dissolved, the solution is left to cool to a temperature of 30-40° C, and then to a temperature of 0-5° C in a water/ice bath, maintaining it under these conditions for 1 hour. The resulting suspension is filtered and the solid retained is washed with 20 ml (1 volume) of cold methanol. The solid obtained is dried at 40° C in a vacuum oven to provide 18.65 g of gatifloxacin with a water content of 2.36% by weight.
The overall yield from the compound (II) is 77.7%, with a purity exceeding 99.8% as determined by HPLC chromatography. The content of by-product resulting from demethylation in position 8 of the ring is lower than 0.1% as determined by HPLC chromatography.

Claims

1. A simplified process for preparing gatifloxacin, characterised in that it consists on reacting compound (II)
Figure imgf000011_0001
with a silylating agent of formula ZS1R3, in which Z is Me3SiNH- or C1-, and R is either a C1-C4 alkyl chain or phenyl, within an aprotic polar solvent, to prepare the intermediate compound (V) ,
Figure imgf000011_0002
in which R is either a C1-C4 alkyl chain or phenyl, which without being isolated is then made to react with a boron trifluoride compound to prepare the intermediate compound (III),
Figure imgf000011_0003
which is not isolated and is then made to react with 2- methylpiperazine to obtain the intermediate compound (IV) ,
Figure imgf000011_0004
which without being isolated is made to react with a C1-C4 alcohol chain to prepare gatifloxacin (I) .
2. A process according to Claim 1, characterised in that the silylating agent is hexamethyldisilazane.
3. A process according to Claims 1 and 2, characterised in that the boron trifluoride compound is the complex of boron trifluoride ethyletherate.
4. A process according to Claims 1 to 3, characterised in that preferably the C1-C4 alkyl alcohol is methanol .
5. A process according to Claims 1 to 4, characterised in that the aprotic polar solvent is acetonitryl.
6. A process according to Claims 1 to 5, characterised in that the pH is adjusted to a value ranging between 8.5 and 9.5 with a base, which is a tertiary amine, preferably triethylamine in the reaction of the intermediate compound (III) with 2-methylpiperazin, .
PCT/IB2004/003595 2003-11-13 2004-11-03 Process for preparing gatifloxacin WO2005047260A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP-200302641 2003-11-13
ES200302641A ES2232309B1 (en) 2003-11-13 2003-11-13 SIMPLIFIED PROCEDURE FOR OBTAINING GATIFLOXACINO.

Publications (1)

Publication Number Publication Date
WO2005047260A1 true WO2005047260A1 (en) 2005-05-26

Family

ID=34586125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003595 WO2005047260A1 (en) 2003-11-13 2004-11-03 Process for preparing gatifloxacin

Country Status (2)

Country Link
ES (1) ES2232309B1 (en)
WO (1) WO2005047260A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1832587A1 (en) * 2006-03-10 2007-09-12 Quimica Sintetica, S.A. Method for preparing moxifloxacin and moxifloxacin hydrochloride
US7365201B2 (en) 2006-03-02 2008-04-29 Apotex Pharmachem Inc. Process for the preparation of the boron difluoride chelate of quinolone-3-carboxylic acid
WO2008126384A1 (en) 2007-03-30 2008-10-23 Daiichi Sankyo Company, Limited Method for producing quinolone carboxylic acid derivative
CN102351843A (en) * 2011-08-18 2012-02-15 张家口市格瑞高新技术有限公司 Synthesis method of 2-methyl piperazine lomefloxacin
CN101659654B (en) * 2008-08-28 2013-11-06 四川科伦药物研究有限公司 2-Methylpiperazine fluoroquinolone compound and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610958A2 (en) * 1988-07-20 1994-08-17 Ube Industries, Ltd. Intermediates in the preparation of 4-oxoquinoline-3-carboxylic acid derivatives
ES2077490A1 (en) * 1992-11-18 1995-11-16 Marga Investigacion Trimethyl silicon esters and chelate solvates of quinoline-3-carboxylic acids. Preparation and application to the quinolone process

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1019114B (en) * 1986-03-31 1992-11-18 三共株式会社 Quinoline-3-carboxylic acid derivatives and the prepn. method thereof
JPH0778065B2 (en) * 1990-07-06 1995-08-23 杏林製薬株式会社 (6,7-Substituted-8-alkoxy-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid-O ▲ above 3 ▼, O ▲ above 4) bis (acyloxy-O) Boron compound, salt thereof, and method for producing the same
NO304832B1 (en) * 1992-05-27 1999-02-22 Ube Industries Aminokinolone derivatives and anti-HIV agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610958A2 (en) * 1988-07-20 1994-08-17 Ube Industries, Ltd. Intermediates in the preparation of 4-oxoquinoline-3-carboxylic acid derivatives
ES2077490A1 (en) * 1992-11-18 1995-11-16 Marga Investigacion Trimethyl silicon esters and chelate solvates of quinoline-3-carboxylic acids. Preparation and application to the quinolone process

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365201B2 (en) 2006-03-02 2008-04-29 Apotex Pharmachem Inc. Process for the preparation of the boron difluoride chelate of quinolone-3-carboxylic acid
EP1832587A1 (en) * 2006-03-10 2007-09-12 Quimica Sintetica, S.A. Method for preparing moxifloxacin and moxifloxacin hydrochloride
WO2008126384A1 (en) 2007-03-30 2008-10-23 Daiichi Sankyo Company, Limited Method for producing quinolone carboxylic acid derivative
CN101652357A (en) * 2007-03-30 2010-02-17 第一三共株式会社 Method for producing quinolone carboxylic acid derivative
US7875722B2 (en) 2007-03-30 2011-01-25 Daiichi Sankyo Company, Limited Method for producing quinolone carboxylic acid derivative
JP5282029B2 (en) * 2007-03-30 2013-09-04 第一三共株式会社 Preparation of quinolonecarboxylic acid derivatives
KR101419087B1 (en) 2007-03-30 2014-07-11 다이이찌 산쿄 가부시키가이샤 Method for producing quinolone carboxylic acid derivative
CN101659654B (en) * 2008-08-28 2013-11-06 四川科伦药物研究有限公司 2-Methylpiperazine fluoroquinolone compound and preparation method and application thereof
CN102351843A (en) * 2011-08-18 2012-02-15 张家口市格瑞高新技术有限公司 Synthesis method of 2-methyl piperazine lomefloxacin

Also Published As

Publication number Publication date
ES2232309B1 (en) 2006-08-01
ES2232309A1 (en) 2005-05-16

Similar Documents

Publication Publication Date Title
EP2069280B1 (en) Process and intermediates for preparing HIV integrase inhibitors
EP2641897B1 (en) A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof
EP1832587B1 (en) Method for preparing moxifloxacin and moxifloxacin hydrochloride
US9133188B2 (en) Methods for preparing naphthyridines
KR20150040340A (en) Process and intermediates for preparing integrase inhibitors
US20190382352A1 (en) Method for Producing Intermediate of Biotin and Method for Producing Biotin
US8258299B2 (en) Process for preparation of temsirolimus
US20100029938A1 (en) Process for the preparation of an antibacterial quinolone compound
CN107325082B (en) Preparation method of high-purity afatinib
CN111704573A (en) Preparation method of rabeprazole chloride and intermediate thereof
WO2017163257A1 (en) Process for preparing pure lh-pyrazolo[3,4-d] pyrimidine derivative
WO2005047260A1 (en) Process for preparing gatifloxacin
EP2276740B1 (en) Improved process for preparing quinoline-3-carboxamide derivatives
CN106565626B (en) Synthesis method of 2-amino-4-aryl-5-methylthiothiazole compound
CN108602850A (en) It is a kind of Austria shellfish cholic acid and its intermediate preparation method
CN113336703B (en) Synthesis of 1,3,4, 5-tetrasubstituted 1H-pyrazole derivatives
JP6452575B2 (en) Manufacturing method of mirtazapine
CZ304984B6 (en) Enhanced process for preparing and novel intermediates of elvitegravir synthesis
JP6963435B2 (en) Method for producing intermediate of biotin and method for producing biotin
CN110734364A (en) Synthesis method of 1- (4-chlorphenyl) -2-cyclopropyl-1-acetone
EP2835371B1 (en) Industrial method for manufacturing high-purity methiozoline
RU2315747C2 (en) Method for production of acetylene compound
EP2448916B1 (en) Production of trans-4-aminocyclopent-2-ene-1-carboxylic acid derivatives
WO2008023383A1 (en) Novel process for the preparation of telithromycin
KR102188341B1 (en) Method for Preparation of Apixaban

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC, FORM 1205A DATED 31.08.2006

122 Ep: pct application non-entry in european phase